Chapter 6 - GRANDMA’S BLUE CABINETMy grandmother, June Bennett, never trusted computers.
She died at eighty-seven with three email addresses because she forgot the password to each previous one.
But she trusted paper.
Receipts.
Contracts.
Tax returns.
Birthday cards.
She kept everything.
When Mercer Biomedical started, Grandma June offered us her basement for storage.
Grant mocked the arrangement.
“Fortune 500 companies don't operate out of suburban basements.”
Grandma looked him straight in the eye.
“Then become Fortune 500 and move your boxes.”
I should have known then she saw through him better than I did.
Rachel and I drove to Grandma’s old house outside Oak Park the following morning.
Our cousin now owned it but had never cleared the basement.
The blue cabinet remained exactly where Grandma left it.
Third drawer.
Behind forty years of property-tax records.
A folder labeled:
CLAIRE + GRANT COMPANY — IMPORTANT
Rachel held it up.
“She really labeled it like you were opening a lemonade stand.”
“We basically were.”
Inside were copies of Mercer’s original articles of incorporation.
Board consents.
Founder agreements.
Bank statements.
And the document Daniel needed most.
A notarized certification of my founder shares dated eleven years and nine months earlier.
Original ink.
Original seal.
Original law-firm witness signatures.
The supposedly fraudulent shares were unquestionably legitimate.
But underneath those papers was something else.
A sealed envelope.
My name was written across the front.
Claire — only if something goes wrong with Grant.
My hands froze.
Rachel read it over my shoulder.
“That's ominous.”
Grandma had died four years earlier.
I had never seen the envelope.
I opened it.
Inside was a single handwritten page.
Claire,
If you're reading this, I'm guessing the charming young man finally became too charming for his own good.
I smiled despite the sting behind my eyes.
Grandma continued:
When I invested my first $75,000, your attorney created a conversion agreement. Grant later asked me to sign an amendment transferring my rights to him. I refused.
I did not tell you because at the time I hoped he was merely ambitious.
Ambition is useful.
Entitlement is dangerous.
The rights remained in my trust.
They pass to you.
Don't use them to punish him.
Use them if you ever need to protect what you built.
Love,
Grandma
My heart started pounding.
“What rights?” Rachel asked.
I dug deeper into the folder.
Then I found them.
Grandma June had invested in Mercer Biomedical during our first formal funding round.
Her shares were modest.
But her agreement contained a forgotten anti-dilution provision tied specifically to founder-control disputes.
My hands began to shake.
“Call Daniel.”
Thirty minutes later, we had him on video.
He read the documents silently.
Then removed his glasses.
“Claire.”
“What?”
“Your grandmother may have just changed the entire company.”
“How?”
“Her original investment converted into preferred shares during the Series B financing.”
“I know.”
“No, you don't understand. These aren't ordinary preferred shares.”
He held a page toward the camera as if we could somehow read it through his screen.
“In the event of founder misconduct triggering dissolution or restructuring, these shares gain enhanced conversion rights.”
Rachel frowned.
“In English?”
Daniel looked at me.
“If Grant forces a restructuring or bankruptcy event, Claire could become the single largest voting shareholder.”
Silence.
Then Rachel burst out laughing.
I didn't.
Because I suddenly understood why Grant once tried to get Grandma to sign an amendment.
He remembered.
Maybe not the details.
But enough.
“Grant knew about this.”
“Probably.”
“So the investor demand letter…”
“Might be designed to trigger financial instability.”
I felt sick.
“He's trying to force a restructuring.”
“Possibly.”
“Because he thinks he can buy distressed shares through another entity.”
Daniel went quiet.
Then said, “That would fit.”
Grant wasn't burning down Mercer blindly.
He was trying to make the company cheap enough to steal back.
We returned to Evanston with the documents locked in Rachel’s bag.
At 2:15 p.m., Daniel filed authenticated copies with the board.
At 3:40, the investor group withdrew its demand pending independent review.
At 4:05, Grant called from a blocked number.
I answered.
“You found the cabinet.”
No hello.
No denial.
Just that.
I looked out my kitchen window.
Snow had started falling softly.
“Grandma always liked you, you know.”
“No, she didn't.”
I smiled.
“You noticed.”
“She didn't understand business.”
“She understood you.”
Grant exhaled.
“Claire, listen to me carefully. The company cannot survive this investigation.”
“Why?”
“Because you don't know everything.”
“Then tell me.”
“I can't over the phone.”
“Email Daniel.”
“I need to speak to you.”
“No.”
“Please.”
That word stunned me.
Grant did not say please.
Not anymore.
“What haven't I found?”
Silence.
Then:
“The CardioNova money isn't the worst thing.”
A chill moved through me.
“What is?”
Grant spoke so quietly I nearly missed it.
“The clinical trial.”
My stomach dropped.
“What clinical trial?”
“The pediatric monitoring study.”
I remembered it.
Three years earlier, Mercer Biomedical tested a wearable cardiac monitor designed for children with congenital heart conditions.
The study was considered a breakthrough.
It helped secure one of our largest government contracts.
“What about it?”
“The data wasn't clean.”
I gripped the counter.
“What does that mean?”
“It means we had failures.”
“How many?”
“Claire—”
“How many?”
“Enough.”
I closed my eyes.
“Did anyone get hurt?”
Another silence.
“Grant.”
“One child had a serious event.”
The room seemed to tilt.
“What kind of event?”
“The monitor missed an arrhythmia.”
“Did the child survive?”
“Yes.”
I breathed again.
“But the event should have been reported differently.”
“Differently how?”
“I was told the engineering team classified it as unrelated.”
“Who told them?”
Grant didn't answer.
I already knew.
“You did.”
“I was protecting the study.”
“You hid a safety failure?”
“It wasn't that simple!”
“A child could have died.”
“But didn't.”
I had never hated Grant until that moment.
Not for Madison.
Not for the money.
Not for the divorce.
This was different.
“You're going to tell regulators everything.”
“I can't.”
“You can.”
“They'll prosecute me.”
“Then maybe you should have thought about that before gambling with somebody else's child.”
He shouted, “I built that device!”
“And that's why you should have cared whether it worked!”
Silence.
Then Grant said something unexpected.
“I have the original data.”
“Where?”
“Somewhere safe.”
“Give it to Daniel.”
“I want a deal.”
Of course.
“What deal?”
“I cooperate. You protect my remaining shares.”
“No.”
“Claire—”
“No.”
“They're Sophie's inheritance too.”
“Stop using our daughter as your bargaining chip.”
“I'm trying to leave her something.”
“You could start with the truth.”
I hung up.
That night, I sat beside Sophie's crib long after she fell asleep.
A missed arrhythmia.
A child wearing a device we built.
A family trusting the name Mercer Biomedical.
I had wanted to save the company.
Now I had to ask a harder question.
Did the company deserve saving?
The answer came at 11:03 p.m.
An email reached my private inbox.
No message.
Just one attachment.
Clinical data.
Thousands of pages.
The sender address was anonymous.
But the final page contained a note.
Ask Grant why patient 041 disappeared from the final report.
I opened the patient index.
Patient 039.
Patient 040.
Patient 042.
No 041.
May you like
Somebody had deleted a child.
And I intended to find out why.
Related Stories
